Low serum S100A6 levels are associated RP-ILD risk in anti-MDA5-positive dermatomyositis
Clinical Rheumatology · 2025
DOI: 10.1007/s10067-024-07265-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Wei Yan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China. Hauptthemen laut MEDLINE: Dermatomyositis, Lung Diseases, Interstitial, Interferon-Induced Helicase, IFIH1, S100 Calcium Binding Protein A6. Die Arbeit nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Northern Jiangsu People's Hospital.
Abstract (Originalsprache)
INTRODUCTION: Anti-MDA5-positive dermatomyositis (anti-MDA5-DM) is a rare autoimmune disease that often leads to rapid-progressive interstitial lung disease (RP-ILD). The lack of effective prediction and treatment methods makes RP-ILD a major risk factor for death in patients with this condition. S100A6 is a member of the S100 Ca2 + - binding protein family, which plays important roles in inflammation, tumor, injury, and fibroblast reparation. This study aims to explore the correlation between serum S100A6 and RP-ILD in anti-MDA5-DM, and to determine whether S100A6 can be used as a specific biomarker to predict RP-ILD. METHODS: The authors enrolled 80 participants, including 20 healthy volunteers, 20 patients with anti-synthase syndrome, and 40 patients with anti-MDA5-positive dermatomyositis. Serum samples were collected and the levels of S100A6 were measured using ELISA. Logistic regression was used to analyze the relationship between serum S100A6 levels and RP-ILD, along with other clinical and laboratory parameters. RESULTS: Serum S100A6 levels were significantly lower in anti-MDA5-DM patients with RP-ILD than those without RP-ILD (odds ratio:0.393 (95% CI, 0.164-0.943, p = 0.036)). High serum S100A6 level was found to be a protective factor for RP-ILD. This study shows that high serum S100A6 level may be a protective factor for RP-ILD in anti-MDA5-DM patients. Serum S100A6 may be used as a specific biomarker to predict whether RP-ILD occurs in anti-MDA5-DM. Key Points • This research discovers and reports a biomarker (S100A6) for distinguishing potential RP-ILD in Anti-MDA5 positive dermatomyositis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China.
- Division of Rheumatology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
- Division of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China. yzweihua2018@163.com.
Förderung
- National Natural Science Foundation of China
- Northern Jiangsu People's Hospital
Zitieren
APA
Yan, W., Wu, Q., Shi, Y., You, H., Jia, J., Meng, D., Ma, L., Zhang, X., Yu, X., Tan, W., & Wei, H. (2025). Low serum S100A6 levels are associated RP-ILD risk in anti-MDA5-positive dermatomyositis. Clinical Rheumatology. https://doi.org/10.1007/s10067-024-07265-z
Vancouver
Yan W, Wu Q, Shi Y, You H, Jia J, Meng D, et al. Low serum S100A6 levels are associated RP-ILD risk in anti-MDA5-positive dermatomyositis. Clinical Rheumatology. 2025. doi:10.1007/s10067-024-07265-z
BibTeX
@article{Yan2025,
author = {Yan, Wei and Wu, Qin and Shi, Yumeng and You, Hanxiao and Jia, Jieting and Meng, Defang and Ma, Li and Zhang, Xuexiang and Yu, Xindi and Tan, Wenfeng and Wei, Hua},
title = {Low serum S100A6 levels are associated RP-ILD risk in anti-MDA5-positive dermatomyositis},
journal = {Clinical Rheumatology},
year = {2025},
doi = {10.1007/s10067-024-07265-z}
}
EUVIMED